Literature DB >> 29046894

Fatty Acid-Mimetic Micelles for Dual Delivery of Antigens and Imidazoquinoline Adjuvants.

Sema Sevimli1, Frances C Knight2, Pavlo Gilchuk3,4, Sebastian Joyce3,4,5, John T Wilson1,2,5.   

Abstract

Vaccine design has undergone a shift towards the use of purified protein subunit vaccines, which offer increased safety and greater control over antigen specificity, but at the expense of immunogenicity. Here we report the development of a new polymer-based vaccine delivery platform engineered to enhance immunity through the co-delivery of protein antigens and the Toll-like receptor 7 (TLR7) agonist imiquimod (IMQ). Owing to the preferential solubility of IMQ in fatty acids, a series of block copolymer micelles with a fatty acid-mimetic core comprising lauryl methacrylate (LMA) and methacrylic acid (MAA), and a poly(ethylene glycol) methyl ether methacrylate (PEGMA) corona decorated with pyridyl disulfide ethyl methacrylate (PDSM) moieties for antigen conjugation were synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization. Carriers composed of 50 mole% LMA (LMA50) demonstrated the highest IMQ loading (2.2 w/w%) and significantly enhanced the immunostimulatory capacity of IMQ to induce dendritic cell maturation and proinflammatory cytokine production. Conjugation of a model antigen, ovalbumin (OVA), to the corona of IMQ-loaded LMA50 micelles enhanced in vitro antigen uptake and cross-presentation on MHC class I (MHC-I). A single intranasal (IN) immunization of mice with carriers co-loaded with IMQ and OVA elicited significantly higher pulmonary and systemic CD8+ T cell responses and increased serum IgG titer relative to a soluble formulation of antigen and adjuvant. Collectively, these data demonstrate that rationally designed fatty acid-mimetic micelles enhance intracellular antigen and IMQ delivery and have potential as synthetic vectors for enhancing the immunogenicity of subunit vaccines.

Entities:  

Keywords:  Imiquimod; RAFT polymerization; Toll-like receptor 7; block copolymer micelles; mucosal immunity; subunit vaccine

Year:  2016        PMID: 29046894      PMCID: PMC5642296          DOI: 10.1021/acsbiomaterials.6b00408

Source DB:  PubMed          Journal:  ACS Biomater Sci Eng        ISSN: 2373-9878


  82 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 2.  Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles.

Authors:  Ugo Bilati; Eric Allémann; Eric Doelker
Journal:  Eur J Pharm Biopharm       Date:  2005-04       Impact factor: 5.571

3.  Generation of peptide-MHC class I complexes through UV-mediated ligand exchange.

Authors:  Boris Rodenko; Mireille Toebes; Sine Reker Hadrup; Wim J E van Esch; Annemieke M Molenaar; Ton N M Schumacher; Huib Ovaa
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.

Authors:  Anushree Seth; Min Beom Heo; Yong Taik Lim
Journal:  Biomaterials       Date:  2014-06-19       Impact factor: 12.479

5.  Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells.

Authors:  Min Beom Heo; Yong Taik Lim
Journal:  Biomaterials       Date:  2013-10-11       Impact factor: 12.479

6.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

Authors:  Z Shen; G Reznikoff; G Dranoff; K L Rock
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

Review 7.  The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.

Authors:  John P Vasilakos; Mark A Tomai
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

8.  Micellar solubilization of timobesone acetate in aqueous and aqueous propylene glycol solutions of nonionic surfactants.

Authors:  J T Ong; E Manoukian
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

Review 9.  TLR7 and TLR8 as targets in cancer therapy.

Authors:  M P Schön; M Schön
Journal:  Oncogene       Date:  2008-01-07       Impact factor: 9.867

10.  A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7.

Authors:  Christopher B Fox; Sandra J Sivananthan; Malcolm S Duthie; Julie Vergara; Jeffrey A Guderian; Elliot Moon; David Coblentz; Steven G Reed; Darrick Carter
Journal:  J Nanobiotechnology       Date:  2014-04-26       Impact factor: 10.435

View more
  11 in total

1.  Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells.

Authors:  Frances C Knight; Pavlo Gilchuk; Amrendra Kumar; Kyle W Becker; Sema Sevimli; Max E Jacobson; Naveenchandra Suryadevara; Lihong Wang-Bishop; Kelli L Boyd; James E Crowe; Sebastian Joyce; John T Wilson
Journal:  ACS Nano       Date:  2019-10-04       Impact factor: 15.881

2.  Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity.

Authors:  Rui Zhang; Jake S Kramer; Josiah D Smith; Brittany N Allen; Caitlin N Leeper; Xiaolei Li; Logan D Morton; Fabio Gallazzi; Bret D Ulery
Journal:  AAPS J       Date:  2018-06-01       Impact factor: 4.009

Review 3.  Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.

Authors:  Geoffrey M Lynn; Richard Laga; Christopher M Jewell
Journal:  Cancer Lett       Date:  2019-06-08       Impact factor: 8.679

Review 4.  Bionanotechnology for vaccine design.

Authors:  Steven Frey; Ana Castro; Ammar Arsiwala; Ravi S Kane
Journal:  Curr Opin Biotechnol       Date:  2018-03-26       Impact factor: 9.740

5.  A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA.

Authors:  Carcia S Carson; Kyle W Becker; Kyle M Garland; Hayden M Pagendarm; Payton T Stone; Karan Arora; Lihong Wang-Bishop; Jessalyn J Baljon; Lorena D Cruz; Sebastian Joyce; John T Wilson
Journal:  J Control Release       Date:  2022-03-15       Impact factor: 11.467

Review 6.  Polyphosphazene immunoadjuvants: Historical perspective and recent advances.

Authors:  Alexander K Andrianov; Robert Langer
Journal:  J Control Release       Date:  2020-12-05       Impact factor: 9.776

Review 7.  Engineering self-assembled materials to study and direct immune function.

Authors:  Lisa H Tostanoski; Christopher M Jewell
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

8.  Structural Optimization of Polymeric Carriers to Enhance the Immunostimulatory Activity of Molecularly Defined RIG-I Agonists.

Authors:  Max E Jacobson; Kyle W Becker; Christian R Palmer; Lucinda E Pastora; R Brock Fletcher; Kathryn A Collins; Olga Fedorova; Craig L Duvall; Anna M Pyle; John T Wilson
Journal:  ACS Cent Sci       Date:  2020-10-26       Impact factor: 14.553

9.  A Polylactide-Based Micellar Adjuvant Improves the Intensity and Quality of Immune Response.

Authors:  Myriam Lamrayah; Capucine Phelip; Céline Coiffier; Céline Lacroix; Thibaut Willemin; Thomas Trimaille; Bernard Verrier
Journal:  Pharmaceutics       Date:  2022-01-03       Impact factor: 6.321

Review 10.  Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.

Authors:  Sachin Bhagchandani; Jeremiah A Johnson; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2021-05-29       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.